Compare CNDT & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | SGHT |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.6M | 395.5M |
| IPO Year | N/A | 2021 |
| Metric | CNDT | SGHT |
|---|---|---|
| Price | $2.07 | $6.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.23 |
| AVG Volume (30 Days) | ★ 1.2M | 329.1K |
| Earning Date | 02-11-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,072,000,000.00 | $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.37 | $12.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $2.03 |
| 52 Week High | $4.90 | $9.24 |
| Indicator | CNDT | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 35.15 |
| Support Level | $1.98 | $6.39 |
| Resistance Level | $2.10 | $7.55 |
| Average True Range (ATR) | 0.08 | 0.58 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 90.38 | 7.03 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.